Yuanming Xu
![Yuanming Xu Yuanming Xu](https://cytokine-based-drugdevelopment.com/wp-content/uploads/sites/349/2024/04/1566437370849-150x150.jpg)
Company: Pfizer
Job title: Associate Director
Seminars:
Engineered PD1-IL15 Improves Intratumoral CD8+ T cell Function and Antitumor Immunity 9:00 am
Designing PD1-IL15 to deliver stimulation to PD1+ tumor-infiltrating lymphocytes (TIL) while minimally affecting circulating peripheral natural killer (NK) cells and T cells The PD1-IL15 mouse surrogate promotes CD8 T cell-dependent anti-tumor Immunity Enhancing efficacy compared to the combination of aPD1 with an IL-15 SuperagonistRead more
day: Conference Day One
Ensuring Translational Success by Futureproofing Your Program: Preclinical Model Selection & Predictive Biomarker Screening 1:00 pm
Dive into discussions on how to maximize the developability of your pre-clinical cytokine efforts through to the clinic and beyond. Explore the intricacies of preclinical models for cytokine therapeutic development and start early thinking for patient selection and dose profiling. Join this workshop to: Navigate what steps can be taken in early development to improve…Read more
day: Pre-Conference Workshop Day